June 27, 2024 10:42 AM EDTUpdated 04:23 PM
Deals
Pharma

Ab­b­Vie buys Third Rock­'s Cel­sius for $250M to ex­pand IBD pipeline

Kyle LaHucik

Senior Reporter

As Ab­b­Vie con­tin­ues to tout its next gen­er­a­tion of im­munol­o­gy drugs be­hind Hu­mi­ra, it’s buy­ing an ear­ly-stage start­up to boost its longer-term prospects in in­flam­ma­to­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

A service from the Financial Times